Posted by Michael Wonder on 31 Oct 2021
Novartis UK awarded Innovation Passport for investigational therapy
29 October 2021 - Novartis have announced that the investigational oral therapy, iptacopan (LNP023), has been awarded an Innovation Passport for the treatment of C3 glomerulopathy by the MHRA, NICE, and the SMC.
It is currently being investigated in a number of complement-driven renal diseases, alongside one haematological disorder, for patients with high unmet need.
